List view / Grid view
19 May 2015 | By Victoria White
Debiopharm has announced the completion of a Phase III study with triptorelin 6-month formulation in 44 patients with central precocious puberty...
19 May 2015 | By Victoria White
pSivida has announced positive safety data from its ongoing assessment of safety data from its Phase III clinical trial of Medidur for posterior uveitis...
19 May 2015 | By Victoria White
A post-hoc subgroup analysis of a Phase II trial of Celgene’s GED-0301 in patients with active Crohn's disease was presented at Digestive Disease Week...
19 May 2015 | By Victoria White
A new study has found that prescribing patients two or more drugs that do not reach the same parts of the body could accelerate pathogen resistance...
19 May 2015 | By Victoria White
Clinicians aiming to compare the use of proton therapy in the treatment of medulloblastoma with conventional photon radiotherapy...
19 May 2015 | By Victoria White
Angela Merkel addressed delegates on the first morning of the Health Assembly, calling for a new plan to deal with “catastrophes” like the Ebola outbreak...
19 May 2015 | By Victoria White
Regeneron and Sanofi have shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA).
19 May 2015 | By Victoria White
Clinical experience of biosimilar infliximab shows that the treatment is comparable to the reference medicinal product in terms of efficacy and safety...
18 May 2015 | By Victoria White
CPhI Worldwide has announced its Expert Panel for CPhI Worldwide 2015 ahead of the eagerly anticipated annual report (3rd edition)...
18 May 2015 | By Victoria White
The first patient has been dosed in the Phase 2 clinical trial of tipifarnib in patients with locally advanced tumours that carry HRAS mutations...
18 May 2015 | By Victoria White
The FDA has granted Fast Track designations to luspatercept for two separate indications for the treatment of patients with beta-thalassemia...
18 May 2015 | By
Endo is set to acquire privately-held Par Pharmaceutical in a transaction valued at $8.05 billion. The acquisition will expand Endo's generics business...
18 May 2015 | By Victoria White
Data from two Phase 3 studies of Orkambi, an investigational medicine designed to treat the underlying cause of cystic fibrosis, have been published...
18 May 2015 | By Victoria White
Boehringer Ingelheim has acquired Pharmaxis’ investigational drug PXS4728A, to develop it for the treatment of NASH and to prevent its consequences...
18 May 2015 | By Victoria White
Amgen has announced the first results from its global Phase 2 study evaluating the efficacy and safety of AMG 334 for the prevention of episodic migraine...
